Bibaswan Mishra*, Jagannath Sahoo, Prasanna Kumar Dixit


The present involves enhancement of solubility of cinnarizine through designing stable nanosuspensions with an aim to overcome its erratic bioavailability. Powdered nanosuspensions were obtained through controlled precipitation-ultrasonication followed by freeze drying. The formulations were suitably stabilized with poly vinyl alcohol (PVA). We found out the effects of PVA concentration, time of ultrasonication and solvent-antisolvent ratio on various responses in the fabricated Cinnarizine (CIN) nanosuspension (NCIN) through characterization of particle size and zeta potential determination, Differential Scanning Calorimetry (DSC) and X-ray diffraction (XRD). Percent drug content, drug dissolution and saturation solubility were performed to establish the role of process parameters on them. The best set of parameters to get the least particle diameter of 621.08 nm are 0.2% W/V, 15 minutes and 1:40 for PVA concentration, time of ultrasonication and solventantisolvent ratio respectively. The percent dissolution and saturation solubility of NCIN markedly increased with decrease in particle size as compared to the original CIN powder. DSC study showed that there was no interaction occurred between drug and excipients in the final formulation and XRD studies suggested that there was negligible crystalline change in NCIN compared with CIN raw crystals. The nanosuspensions had shown 99.98% drug release in just three minutes. Hence nanosuspensions of cinnarizine had been formulated successfully with high dissolution velocity to eradicate solubility related bioavailability problem.


Cinnarizine, nanosuspension, controlled precipitation, Ultrasonication, In-vitro dissolution.

Full Text:

Full text in pdf


Arieli, R., Shupak, A., Shachal, B., Shenedrey, A.,

Ertracht, O., Rashkovan, G. (1999): Effect of the antimotion-sickness

medication cinnarizine on central

nervous system oxygen toxicity, Under-sea Hyperbar

Med, 26, p. 105–109.

Brough, C., Williams III, R.O. (2013): Amorphous solid

dispersions and nano-crystal technologies for poorly

water-soluble drug delivery, Int J Pharm, 453, p. 157– 166.

Council of Europe, European Pharmacopoeia. (2001):

Council of Europe, Strasburg, p. 636s–638s.

Demirel, M., Yajan, Y., Kalava, B.S. (2005):

Physicochemical characterization and dissolution

properties of cinnarizine solid dispersions, Turk J Pharm

Sci, 2, p. 51–62.

Douroumis, D., Fahr, A. (2007): Stable carbamazepine

colloidal systems using the cosolvent technique, Eur J

Pharm Sci, 30, p. 367–374.

Fenske, D.B., Chonn, A., Cullis, P.R. (2008): Liposomal

nanomedicines: an emerging field, Toxicol Pathol, 36, p.


Gao, L., Zhang, D., Chen, M. (2008): Drug nanocrystals

for the formulation of poorly soluble drugs and its

application as a potential drug delivery system, J Nanopart

Res, 10, p. 845–862.

Grau, M.J., Kayser, O., Müller, R.H. (2000):

Nanosuspensions of poorly soluble drugs - reproducibility

of small-scale production, Int J Pharm, 196, p. 155-157.

Guo, P., Liu, Y.Z., Rong, X.Y., Nie, X.Y. (2006):

Determination of cinnarizine and related substances by

HPLC, J Hebei Univ Sci Technol, 27, p. 214–215.

Kesisoglou, F., Panmai, S., Wu, Y. (2007): Nanosizingoral

formulation development and biopharmaceutical

evaluation, Adv Drug Deliv Rev, 59, p. 631–644.

Lawrence, M.J., Rees, G.D. (2000): Microemulsion-based

media as novel drug delivery systems, Adv Drug Deliv Rev,

, p. 89–101.

Lindfors, L., Forssén, S., Westergren, J., Olsson, U.

(2008): Nucleation and crystal growth in supersaturated

solutions of a model drug, J Colloid Interface Sci, 325, p.


Lindfors, L., Forssn, S., Skantze, P., Skantze, U.,

Zackrisson, A., Olsson, U. (2006a): Amorphous drug

nanosuspensions. 2. Experimental determination of bulk

monomer concentrations, Langmuir, 22, p. 911–916.

Lindfors, L., Skantze, P., Skantze, U., Rasmusson, M.,

Zackrisson, A., Olsson, U. (2006b): Amorphous drug

nanosuspensions. 1. Inhibition of Ostwald ripening,

Langmuir, 22, p. 906–910.

Lipinski, C. (2002): Poor aqueous solubility—an industry

wide problem in drug delivery, Am Pharm Rev, 5, p. 82–85.

Muchow, M., Maincent, P., Müller, R.H. (2008): Lipid

nanoparticles with a solid matrix (SLN®, NLC®, LDC®)

for oral drug delivery, Drug Dev. Ind Pharm, 34, p. 1394–

Müller, R.H., Becker, R., Kruss, B., Peters, K. (1998):

Pharmaceutical nanosuspensions for medicament

administration as system of increased saturation solubility

and rate of solution, US Patent, No. 5858410.

Müller, R.H., Peters, K., Becker, R., Kruss, B. (1995a):

Nanosuspensions — a novel formulation for the i.v.

administration of poorly soluble drugs, 7th Int Conf on

Pharm Technol (APV: APGI), Budapest, p. 491-492.

Neslihan, G.R., Benita, S. (2004): Self-emulsifying drug

delivery systems (SEDDS) for improved oral delivery of

lipophilic drugs, Biomed Pharmacother, 58, p. 173–182.

Ogata, H., Aoyagi, N., Kaniwa, N., Ejima, A., Kitaura, T.,

Ohki, T., Kitamura, K. (1986b): Evaluation of beagle

dogs as an animal model for bioavailability testing of

cinnarizine capsules, Int J Pharm, 29, p. 121-126.

Ogata, H., Aoyagi, N., Kaniwa, N., Ejima, A., Sekine, N.,

Kitamura, M., Inoue, Y. (1986a): Gastric acidity

dependent bioavailability of cinnarizine from two

commercial capsules in healthy volunteers, Int J Pharm, 29,

p. 113-120.

Raghavan SL, Trividic A, Davis AF, Hadgraft J. (2001):

Crystallization of hydrocortisone acetate: influence of

polymers, Int J Pharm, 212, p. 213–221.

Raghupathi, K., Grover, V., Chawla, H.P.S., Garg, S.

(2001): Evaluation of compatibility of Ketorolac

tromethamine with selected polymers and common tablet

excipients by thermal and isothermal stress testing, STP

Pharm Sci, 11, p. 449-457.

Reynolds, J.E.F. (1999): Martindale, The Complete Drug

Reference. 32nd ed. The Pharmaceutical Press, London,

p. 406.

Schultheiss, N., Newman, A. (2009): Pharmaceutical

cocrystals and their physicochemical properties, Crystal

Growth Design, 9, p. 2950–2967.

Serajuddin ATM. (2007): Salt Formation to Improve

Drug Solubility, Adv Drug Delivery Rev, p. 603–616.

Shi, S., Chen, H., Lin, X., Tang, X. (2010):

Pharmacokinetics, tissue distribution and safety of

cinnarizine delivered in lipid emulsion, Int J Pharm, 383, p.


Stella, V.J., He, Q. (2008): Cyclodextrins, Toxicol Pathol,

, p. 30–42.

Stephenson, G.A., Aburub, A., Woods, T.A. (2011):

Physical stability of salts of weak bases in the solid-state, J

Pharm Sci, 100, p. 1607–1617.

Van Eerdenbrugh, B., Froyen, L., Martens, J.A., Blaton,

N., Augustijns, P., Brewster, M., Van den, M. G. (2007):

Characterization of physico-chemical properties and

pharmaceutical performance of sucrose co-freeze-dried

solid nanoparticulate powders of the anti-HIV agent

loviride prepared by media milling, Int J Pharm, 338, p.


Xia, D., Quan, P., Piao, H., Piao, H., Sun, S., Yin, Y., Cui,

F. (2010): Preparation of stable nitrendipine

nanosuspensions using the precipitation–ultrasonication

method for enhancement of dissolution and oral

bioavailability, Eur J Pharm Sci, 40, p. 325–334.

Xiong, R., Lu, W., Li, J., Wang, P., Xu, R., Chen, T.

(2008): Preparation and characterization of intravenously

injectable nimodipine nanosuspension, Int J Pharm, 350, p.


Zimmermann, A., Millqvist-Fureby, A., Elema, M.R.,

Hansen, T., Müllertz, A., Hovgaard, L. (2009): Adsorption

of pharmaceutical excipients onto microcrystals of

siramesine hydrochloride: effects on physicochemical

properties, Eur J Pharm Biopharm, 71, p. 109–116.


  • There are currently no refbacks.

Copyright © 2015 BIOPHARM JOURNAL  - ISSN 2454-1397 & Powered by Sona Nfinity